CFLAR and non-small cell lung carcinoma: Besides the increase in TRAIL-receptors and effects on cFLIP levels [15, 16, 37–39], particularly the Bcl-2 family members NOXA and MCL-1 accumulated in NSCLC cells after bortezomib exposure [39–41].